JAGX (Jaguar Health) EBIT : $-32.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health EBIT?

Jaguar Health's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-7.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-32.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jaguar Health's annualized ROC % for the quarter that ended in Sep. 2024 was -77.13%. Jaguar Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -166.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jaguar Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -114.76%.

Jaguar Health EBIT Historical Data

The historical data trend for Jaguar Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health EBIT Chart

Jaguar Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-32.80

-31.02

-44.18

-35.67

-35.52

Jaguar Health Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-8.79	-8.79	-8.76	-7.20	-7.26

Competitive Comparison of Jaguar Health's EBIT

For the Biotechnology subindustry, Jaguar Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jaguar Health's EV-to-EBIT falls into.

Jaguar Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.00 Mil.

Jaguar Health (NAS:JAGX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jaguar Health's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-29.048 * ( 1 - 0% )	/	( (37.978	+	37.348)	/ 2 )
=	-29.048	/	37.663
=	-77.13 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	61.459	-	7.432	-	( 16.049	-	max(0, 19.133	-	40.111	+	16.049	))
=	37.978

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	58.466	-	7.849	-	( 13.269	-	max(0, 19.874	-	36.643	+	13.269	))
=	37.348

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jaguar Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-29.048	/	( ( (1.664 + max(16.395, 0))	+	(1.533 + max(15.298, 0)) )	/	2 )
=	-29.048	/	( ( 18.059	+	16.831 )	/	2 )
=	-29.048	/	17.445
=	-166.51 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.299	+	9.556	+	13.142)	-	(7.432	+	0.17	+	-3.5527136788005E-15)
=	16.395

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.249	+	9.674	+	12.394)	-	(7.849	+	0.17	+	-3.5527136788005E-15)
=	15.298

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jaguar Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-32.001	/	27.884
	=	-114.76 %

Jaguar Health EBIT Related Terms

Thank you for viewing the detailed overview of Jaguar Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Jaguar Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Pine Street, Suite 400, San Francisco, CA, USA, 94104

Website

http://www.jaguar.health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Executives

Anula Jayasuriya	director	5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi	officer: Chief Scientific Officer	C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte	director, officer: CEO & President	213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak	officer: Chief Accounting Officer	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski	director	C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin	officer: Chief of Staff, CCO & GC	201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel	director	C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994	10 percent owner	23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow	10 percent owner	THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd	10 percent owner	PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser	10 percent owner	11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan	director	C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis	director	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson	director	C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p.	10 percent owner	280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017